The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
To investigate the usefulness of Cyfra 21-1 as an indicator of therapy effectiveness and prognosis in advanced primary lung cancer, sixty-three patients were selected on the basis of a high Cyfra 21-1 serum level (> 3.3 ng/ml) at the time of diagnosis. Serial assays of Cyfra 21-1 were performed during the first three courses of chemotherapy among 63 patients. The serial values were analysed according...
We have investigated the usefulness of Cyfra 21-1 as indicator of therapy effectiveness and prognosis in lung cancer. Forty-two patients with primary lung cancer were selected on the basis of a high Cyfra 21-1 serum level (\gr 3,3 ig/L) at diagnosis time. All cases were histologically proved: 6 small cell carcinomas, 17 squamous cell carcinomas, 11 adenocarcinomas and 8 large cell carcinomas. Serial...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.